Gerald M. Reaven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gerald M. Reaven has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Fahim Abbasi
6 shared publicationsCindy Lamendola
5 shared publications- Fahim Abbasi
Department of Medicine, Stanford University, Stanford, USA
5 shared publications - Tracey McLaughlin
Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, California
4 shared publications C. Lamendola
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA
2 shared publicationsCynthia Lamendola
Stanford University School of Medicine, Department of Medicine, Stanford, CA 94305
2 shared publications
Latest Publications
- Open Access
- 22 March 2016
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 15 (1) , 1-8
Metabolic markers associated with insulin resistance predict type 2 diabetes in Koreans with normal blood pressure or prehypertension
Questions remain as to the association between essential hypertension and increased incidence of type 2 diabetes (T2DM). The premise of this analysis is that insulin resistance/compensatory hyperinsulinemia is a major predictor of T2DM, and the greater the prevalence of insulin resistance within any population, normotensive or hypertensive, the more likely T2DM will develop. The hypothesis to be tested is that surrogate estimates of insulin resistance will predict incident T2DM to a significant degree in persons with normal blood pressure or prehypertension. Analysis of data from a population-based survey of 10, 038 inhabitants of rural and urban areas of Korea, ≥40 years-old, initiated in 2001, with measures of demographic and metabolic characteristics at baseline and 8-years later. Participants were classified as having normal blood pressure or prehypertension, and three simple manifestations of insulin resistance related to the pathophysiology of T2DM used to predict incident T2DM: (1) glycemia (plasma glucose concentration 2-hour after 75 g oral glucose challenge = 2-hour PG); (2) hyperinsulinemia (plasma insulin concentration 2-hour after 75 g oral glucose challenge = 2-hour PI); and (3) dyslipidemia (ratio of fasting plasma triglyceride/high/density lipoprotein cholesterol concentration = TG/HDL-C ratio). Fully adjusted hazard ratios (HR, 95 % CI) for incident T2DM were highest (P < 0.001) in the quartile of individuals with the highest 2-hour PG concentrations, ranging from 5.84 (3.37–10.1) in women with prehypertension to 12.2 (7.12–21.00) in men with normal blood pressure. T2DM also developed to a significantly greater degree in subjects within the highest quartile of TG/HDL-C ratios, with HRs varying from 2.91 (1.63–2.58) in women with prehypertension (P < 0.001) to 1.77 (1.12–2.81, P < 0.05) in men with prehypertension. The least predictive index of insulin resistance was the 2-hour PI concentration. Subjects with normal blood pressure in the highest quartile of 2-hour PI concentrations were significantly associated with incident T2DM, with HRs of 1.5 (1.02–2.20, P = 0.25) and 2.02 (1.35–3.02, P < 0.001), in men and women, respectively. Finally, incidence of T2DM in the highest quartile was somewhat greater in patients with prehypertension, irrespective of predictor. Metabolic variables associated with insulin resistance (glycemia, insulinemia, and dyslipidemia) predict the development of T2DM in patients with either normal blood pressure or prehypertension.
- 22 March 2016
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 15 (1) , 1-8
Open AccessMetabolic markers associated with insulin resistance predict type 2 diabetes in Koreans with normal blood pressure or prehypertension
Questions remain as to the association between essential hypertension and increased incidence of type 2 diabetes (T2DM). The premise of this analysis is that insulin resistance/compensatory hyperinsulinemia is a major predictor of T2DM, and the greater the prevalence of insulin resistance within any population, normotensive or hypertensive, the more likely T2DM will develop. The hypothesis to be tested is that surrogate estimates of insulin resistance will predict incident T2DM to a significant degree in persons with normal blood pressure or prehypertension. Analysis of data from a population-based survey of 10, 038 inhabitants of rural and urban areas of Korea, ≥40 years-old, initiated in 2001, with measures of demographic and metabolic characteristics at baseline and 8-years later. Participants were classified as having normal blood pressure or prehypertension, and three simple manifestations of insulin resistance related to the pathophysiology of T2DM used to predict incident T2DM: (1) glycemia (plasma glucose concentration 2-hour after 75 g oral glucose challenge = 2-hour PG); (2) hyperinsulinemia (plasma insulin concentration 2-hour after 75 g oral glucose challenge = 2-hour PI); and (3) dyslipidemia (ratio of fasting plasma triglyceride/high/density lipoprotein cholesterol concentration = TG/HDL-C ratio). Fully adjusted hazard ratios (HR, 95 % CI) for incident T2DM were highest (P < 0.001) in the quartile of individuals with the highest 2-hour PG concentrations, ranging from 5.84 (3.37–10.1) in women with prehypertension to 12.2 (7.12–21.00) in men with normal blood pressure. T2DM also developed to a significantly greater degree in subjects within the highest quartile of TG/HDL-C ratios, with HRs varying from 2.91 (1.63–2.58) in women with prehypertension (P < 0.001) to 1.77 (1.12–2.81, P < 0.05) in men with prehypertension. The least predictive index of insulin resistance was the 2-hour PI concentration. Subjects with normal blood pressure in the highest quartile of 2-hour PI concentrations were significantly associated with incident T2DM, with HRs of 1.5 (1.02–2.20, P = 0.25) and 2.02 (1.35–3.02, P < 0.001), in men and women, respectively. Finally, incidence of T2DM in the highest quartile was somewhat greater in patients with prehypertension, irrespective of predictor. Metabolic variables associated with insulin resistance (glycemia, insulinemia, and dyslipidemia) predict the development of T2DM in patients with either normal blood pressure or prehypertension.
- 1 September 2011
- Published by Elsevier in Medical Clinics of North America
- Vol. 95 (5) , 875-892
Insulin Resistance: the Link Between Obesity and Cardiovascular Disease
- 1 September 2011
- Published by Elsevier in Medical Clinics of North America
- Vol. 95 (5) , 875-892
Insulin Resistance: the Link Between Obesity and Cardiovascular Disease
- 1 September 2009
- Published by Wiley in Journal of Diabetes
- Vol. 1 (3) , 142-150
Insulin secretory function in Type 2 diabetes: Does it matter how you measure it?
The following estimates of insulin secretory function have been used widely to evaluate the role of pancreatic β-cells in the pathogenesis and treatment of patients with type 2 diabetes (2DM): (i) Homeostatic Model Assessment (HOMA)-β, a calculation based on fasting plasma glucose and insulin concentrations; (ii) post-glucose acute insulin response (AIRg), the increment in insulin concentration measured in the 5 min after intravenous glucose; and (iii) ΔI/ΔG, the ratio of the increment in plasma insulin concentration (I)/increment in plasma glucose concentration (G) 30 min after the oral administration of 75 g glucose. Experiments based on these approaches have led to a widely held point of view that that the natural history of 2DM is characterized by a progressive increase in the magnitude of hyperglycemia, secondary to an inexorable decline in pancreatic β-cell function: the greater the increase in plasma glucose concentration, the greater the impairment of the ability of the pancreas to secrete insulin. In the present review, theoretical questions are raised as to the physiological validity of these estimates of insulin secretory function and experimental data are presented demonstrating that hourly measurements of plasma insulin and glucose concentrations in response to mixed meals throughout an 8-h day lead to a very different point of view. Studies are also reviewed that question the 'inexorability' of the changes in insulin secretory function that have been reported. It is concluded that it may be time to challenge current conventional wisdom as to the role of the β-cell in the natural history of 2DM.
- 1 September 2009
- Published by Wiley in Journal of Diabetes
- Vol. 1 (3) , 142-150
Insulin secretory function in Type 2 diabetes: Does it matter how you measure it?
The following estimates of insulin secretory function have been used widely to evaluate the role of pancreatic β-cells in the pathogenesis and treatment of patients with type 2 diabetes (2DM): (i) Homeostatic Model Assessment (HOMA)-β, a calculation based on fasting plasma glucose and insulin concentrations; (ii) post-glucose acute insulin response (AIRg), the increment in insulin concentration measured in the 5 min after intravenous glucose; and (iii) ΔI/ΔG, the ratio of the increment in plasma insulin concentration (I)/increment in plasma glucose concentration (G) 30 min after the oral administration of 75 g glucose. Experiments based on these approaches have led to a widely held point of view that that the natural history of 2DM is characterized by a progressive increase in the magnitude of hyperglycemia, secondary to an inexorable decline in pancreatic β-cell function: the greater the increase in plasma glucose concentration, the greater the impairment of the ability of the pancreas to secrete insulin. In the present review, theoretical questions are raised as to the physiological validity of these estimates of insulin secretory function and experimental data are presented demonstrating that hourly measurements of plasma insulin and glucose concentrations in response to mixed meals throughout an 8-h day lead to a very different point of view. Studies are also reviewed that question the 'inexorability' of the changes in insulin secretory function that have been reported. It is concluded that it may be time to challenge current conventional wisdom as to the role of the β-cell in the natural history of 2DM.
- 1 July 2009
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 43 (11) , 997-1002
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment
- 1 July 2009
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 43 (11) , 997-1002
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment
- 28 May 2009
- Published by Springer Nature
- No. 193,p. 271-295
A1 Adenosine Receptor: Role in Diabetes and Obesity
Adenosine mediates its diverse effects via four subtypes (A1, A2A, A2B and A3) of G-protein-coupled receptors. The A1 adenosine receptor (A1AR) subtype is the most extensively studied and is well characterized in various organ systems. The A1ARs are highly expressed in adipose tissue, and endogenous adenosine has been shown to tonically activate adipose tissue A1ARs. Activation of the A1ARs in adipocytes reduces adenylate cyclase and cAMP content and causes inhibition of lipolysis. The role of A1ARs in lipolysis has been well characterized by using several selective A1AR agonists as well as A1AR knockout mice. However, the contribution of A1ARs to the regulation of lipolysis in pathological conditions like insulin resistance, diabetes and dyslipidemia, where free fatty acids (FFA) play an important role, has not been well characterized. Pharmacological agents that reduce the release of FFA from adipose tissue and thus the availability of circulating FFA have the potential to be useful for insulin resistance and hyperlipidemia. Toward this goal, several selective and efficacious agonists of the A1ARs are now available, and some have entered early-phase clinical trials; however, none have received regulatory approval yet. Here we review the existing knowledge on the role of A1ARs in insulin resistance, diabetes and obesity, and the progress made in the development of A1AR agonists as antilipolytic agents, including the challenges associated with this approach.
- 28 May 2009
- Published by Springer Nature
- No. 193,p. 271-295
A1 Adenosine Receptor: Role in Diabetes and Obesity
Adenosine mediates its diverse effects via four subtypes (A1, A2A, A2B and A3) of G-protein-coupled receptors. The A1 adenosine receptor (A1AR) subtype is the most extensively studied and is well characterized in various organ systems. The A1ARs are highly expressed in adipose tissue, and endogenous adenosine has been shown to tonically activate adipose tissue A1ARs. Activation of the A1ARs in adipocytes reduces adenylate cyclase and cAMP content and causes inhibition of lipolysis. The role of A1ARs in lipolysis has been well characterized by using several selective A1AR agonists as well as A1AR knockout mice. However, the contribution of A1ARs to the regulation of lipolysis in pathological conditions like insulin resistance, diabetes and dyslipidemia, where free fatty acids (FFA) play an important role, has not been well characterized. Pharmacological agents that reduce the release of FFA from adipose tissue and thus the availability of circulating FFA have the potential to be useful for insulin resistance and hyperlipidemia. Toward this goal, several selective and efficacious agonists of the A1ARs are now available, and some have entered early-phase clinical trials; however, none have received regulatory approval yet. Here we review the existing knowledge on the role of A1ARs in insulin resistance, diabetes and obesity, and the progress made in the development of A1AR agonists as antilipolytic agents, including the challenges associated with this approach.
- 17 March 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 180 (6) , 601-602
Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus?
The perceived need for introducing metabolic syndrome as a diagnostic category was to identify individuals at increased risk of cardiovascular disease whose primary abnormality is not an elevated low-density lipoprotein cholesterol level.[1][1],[2][2] Identification of such individuals would permit
- 17 March 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 180 (6) , 601-602
Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus?
The perceived need for introducing metabolic syndrome as a diagnostic category was to identify individuals at increased risk of cardiovascular disease whose primary abnormality is not an elevated low-density lipoprotein cholesterol level.[1][1],[2][2] Identification of such individuals would permit
- 31 October 2008
- Published by Elsevier in Metabolism
- Vol. 57 (10) , 1355-1360
Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation
- 31 October 2008
- Published by Elsevier in Metabolism
- Vol. 57 (10) , 1355-1360
Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation
- 1 September 2008
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 37 (3) , 581-601
Insulin Resistance: the Link Between Obesity and Cardiovascular Disease
- 1 September 2008
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 37 (3) , 581-601
Insulin Resistance: the Link Between Obesity and Cardiovascular Disease
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (5) , 785-787
Why a Cluster is Truly a Cluster: Insulin Resistance and Cardiovascular Disease
- 1 May 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (5) , 785-787
Open AccessWhy a Cluster is Truly a Cluster: Insulin Resistance and Cardiovascular Disease